103P - Comparative analysis of incidence and trend of non-hematologic toxicities in advanced non-small-cell lung cancer patients treated with EGFR TKIs

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Complications of Treatment
Non-Small-Cell Lung Cancer, Metastatic
Presenter Antonio Passaro
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A. Passaro, E. Del Signore, F. de Marinis
  • Division Of Thoracic Oncology, European Institute of Oncology, 20141 - Milan/IT


Rash and diarrhoea are frequently observed in patients receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in advanced non-small-cell lung cancer (NSCLC). Nowadays, three different EGFR TKIs are approved for the treatment of patients harbouring EGFR mutations, though these drugs showed different safety profile. Among patients treated with afatinib, erlotinib and gefitinib, we performed a retrospective comparative analysis evaluating the incidence and trend of rash and diarrhoea, before and after correct management.